Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ziphius NV is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner and is situated within 1 distinct art unit. This prosecution profile shows a singular focus, with the company's current pharmaceutical patent efforts concentrated in 1 specific matter at the USPTO.
The busiest examiner for the company is HOERNER, PAUL ELLSWORTH, who is responsible for 1 busiest examiner pending action. As there is only 1 pending office action in total, this examiner is the only individual currently reviewing the company's pending claims in the Biotechnology & Pharmaceuticals sector. The involvement of 1 distinct art unit indicates that the prosecution is occurring within a single specialized technical group. This concentrated activity in 1 distinct art unit and with 1 distinct examiner means that the company's immediate patent goals in this area are tied to the results of this 1 specific examination.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOERNER, PAUL ELLSWORTH | 1 | 50.6% | +62.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705454 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | HOERNER, PAUL ELLSWORTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705454 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | HOERNER, PAUL ELLSWORTH | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705454 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | HOERNER, PAUL ELLSWORTH | 1645 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZiphius NV has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul Ellsworth Hoerner has the most, with 1 of Ziphius NV's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
